Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: Study design and rationale of a phase III clinical programme

Clinical Drug Investigation

Volumn 28, Issue 10, 2008, Pages 625-634

  Jones, Peter H ^a,e   Bays, Harold E ^b   Davidson, Michael H ^c   Kelly, Maureen T ^d   Buttler, Susan M ^d   Setze, Carolyn M ^d   Sleep, Darryl J ^d   Stolzenbach, James C ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d ABBOTT LABORATORIES   (United States)

^e NONE   (United States)

Author keywords

Atherosclerosis; Atorvastatin, therapeutic use; Choline fenofibrate, therapeutic use; Clinical trial design; Coronary disorders; HMG CoA reductase inhibitors, therapeutic use; Lipid metabolism disorders; Research and development

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSLIPIDEMIA; EVALUATION; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; PROCETOFEN; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; RESEARCH DESIGN; SIMVASTATIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 51549122051     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828100-00003     Document Type: Article

References (46)

1. Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992 Dec 14; 70 (19): 10H-3H
2. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992 Sep 15; 70 (7): 733-7
3. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 May; 62 (5): 707-14
4. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992 Jan; 85 (1): 37-45
5. Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005 Apr 5; 45 (7): 1003-12
6. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 Sep 27; 357 (13): 1301-10
7. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2002 Aug; 2 (3): 325-33
8. Minino AM, Heron MP, Murphy SL, et al. Deaths: final data for 2004. Natl Vital Stat Rep 2007, 55: 1-119
9. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 Jan 30; 115 (4): 450-8
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421
11. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007 Jan; 30 Suppl. 1: S4-S41
12. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 Sep; 14 Suppl. 2: S1-113
13. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
14. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39
15. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002 Jul 15; 90 (2): 139-43
16. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006 Nov 1; 98 (9): 1231-3
17. Ansell BJ, Fonarow GC, Maki KC, et al. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 2006 Nov; 152 (5): 976-81
18. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004 Oct; 27 (10): 2444-9
19. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm 2006 Nov-Dec; 12 (9): 745-51
20. Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007 Mar; 23 (3): 553-63
21. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 Jul 29; 108 (4): 414-9
22. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 Dec; 91 Suppl. 5: v1-52
23. Keevil JG, Cullen MW, Gangnon R, et al. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 2007 Mar 20; 115 (11): 1363-70
24. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999 May 1; 83 (9): 1303-7
25. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006 Aug; 119 (8): 676-83
26. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996 Apr; 3 (2): 213-9
27. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008 Feb 19; 51 (7): 724-30
28. Goldberg AC. Combination therapy of dyslipidemia. Curr Treat Options Cardiovasc Med 2007 Aug; 9 (4): 249-58
29. Miller M. Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy? Prev Cardiol 2007 Winter; 10 (1): 31-5
30. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001 Jul-Aug; 35 (7-8): 908-17
31. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002 Mar 7; 89 (5A): 50C-7C
32. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia. A review. Curr Med Res Opin 2003; 19 (3): 155-68
33. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002 Jul; 25 (7): 1198-202
34. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004 May; 64 (2): 137-51
35. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005 Feb 15; 95 (4): 462-8
36. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005 May 17; 45 (10): 1649-53
37. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006 Jan; 5 (1): 145-56
38. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004; 6 148-57
39. Zocor (simvastatin) product package insert. West Point (PA): Merck & Co., Inc., Jun 2008
40. Lipitor (atorvastatin calcium) product package insert. New York (NY): Pfizer Inc., Nov 2007
41. Crestor (rosuvastatin calcium) product package insert. Wilmington (DE): AstraZeneca Pharmaceuticals LP, Nov 2007
42. TriCor (fenofibrate tablets) product package insert. Abbott Park (IL): Abbott, Oct 2007
43. American Heart Association. An eating plan for healthy Americans: our American Heart Association diet. AHA publication no. 50-1481A
44. Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing. 2nd ed. Washington, DC: AACC Press, 2000
45. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 Jul 15; 92 (2): 152-60
46. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 May 16; 113 (19): 2363-72